Roussos Lab

“We generate single cell and cell type-specific multi-scale omics data in the human brain to better understand the genetic architecture and etiopathogenesis of neuropsychiatric diseases.”

Panos Roussos is a Professor of Psychiatry and Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai and Director of the Pamela Sklar Division of Psychiatric Genomics. He is a member of Icahn Institute for Data Science and Genomic Technology and Friedman Brain Institute. He is also a VA/MIRECC Research Physician at the James J. Peters VA Medical Center. He received his medical and doctorate degrees from the University of Crete in Greece and he completed his residency in Psychiatry (research track) at Icahn School of Medicine at Mount Sinai followed by a MIRECC research fellowship in schizophrenia. His early research focused on the genetic exploration of intermediate cognitive phenotypes, including the prepulse inhibition of the startle reflex in human subjects and restoration of deficits using a pharmacogenomic approach. During his residency in psychiatry (Physician-Scientist Research Track) at Icahn School of Medicine at Mount Sinai, he worked on human postmortem studies by integrating genomics with gene expression and gene network approaches. His research focuses on the integration of high-dimensional data, such as genomic, epigenomic, and transcriptomic, using advanced biostatistical methods in order to identify some of the mechanisms through which risk genetic variants increase the risk for neuropsychiatric diseases.

Panos Roussos M.D. Ph.D.

Professor at the Department of Genetics and Genomics Sciences and the Department of Psychiatry
Director of the Pamela Sklar Division of Psychiatric Genomics
Icahn Institute for Data Science and Genomic Technology
Friedman Brain Institute
Icahn School of Medicine at Mount Sinai

Projects

Overview
Functional characterization of non-coding variants for Alzheimer’s disease
Multi-scale analysis in schizophrenia and bipolar disorder

 

Large-scale transcriptome and epigenome association analysis across multiple traits

Supported by Veterans Administration (Merit BX004189).

Precision Medicine refers to the customization of medical treatment to the individual characteristics of each patient. The Million Veteran Program (MVP) provides a unique opportunity to perform large-scale genome-wide association studies (GWAS) across multiple traits and diseases towards the successful application of Precision Medicine. While well powered GWAS have identified multiple risk variants, due to their small effect sizes there has been limited conclusive findings on the genetic factors contributing to complex traits. In addition, the majority of common risk variants are within non-coding regions of the genome and, as such, the functional relevance of most discovered loci remains unclear. Our group and others have shown that a large proportion of phenotypic variability in disease risk can be explained by regulatory variants, i.e. genetic variants that affect epigenetic mechanisms and the expression levels of genes. The  study of gene expression and epigenome changes directly in the MVP samples is not feasible as such data are not available.

To overcome these limitations, we propose to apply a machine learning approach that leverages existing molecular data (unrelated to MVP) as a reference panel to directly impute multi-tissue and genome-wide gene expression and epigenome profiles in MVP samples using existing MVP genotypes. As reference panel, we will use large-scale datasets with genotyping and molecular profiling that our group and others have generated, including, but not limited to, the PsychENCODE project, CommonMind Consortium and Accelerating Medicine Partnership for Alzheimer’s Disease. Imputed MVP gene expression and epigenome data provides a powerful cohort to “translate” genetic findings to the dysregulation of specific molecular pathways across multiple traits that will enhance drug discovery.

The 3D genome in transcriptional regulation across the postnatal life span
Understanding the role of human brain immune cells in Alzheimer Disease vulnerability
Multiregional assessment of gene expression and chromatin accessibility in human brain tissue

Awards & Honors

 

2020:    Eva King Killam Research Award for excellence in Translational Research, American College of Neuropsychopharmacology
2017-:   Member , American College of Neuropsychopharmacology
2016:    Presidential Early Career Awards for Scientists and Engineers, White House
2015:    Elected to attend and Awarded Funds, Charleston Conference on Alzheimer’s Disease
2013:    Best Research Paper, New York State Psychiatric Association Scientific Paper Contest
2013:    Travel Award , International Congress on Schizophrenia Research
2013-:   Associate Member , American College of Neuropsychopharmacology
2012:    Domestic Travel Fellowship Award, Society of Biological Psychiatry
2012:    Research Colloquium for Junior Investigators – Travel Award , American Psychiatric Association
2012:    Best Research Paper, New York State Psychiatric Association Scientific Paper Contest
2012:    Travel Award , American College of Neuropsychopharmacology
2012:    Early Academic Career Award, APA/Merck
2011:    Best Research Paper, New York State Psychiatric Association Scientific Paper Contest
2010:    Outstanding Resident Award, National Institute of Mental Health
2010:    Travel Award, International Society of Psychiatric Genetics

Active Funding

 

2019 – 2024: R01AG067025, National Institute of Aging (Roussos PI)
Understanding the molecular mechanisms that contribute to neuropsychiatric symptoms in Alzheimer Disease.


2020 – 2025: R01AG065582, National Institute of Aging (Roussos PI)
Understanding the protective and neuroinflammatory role of human brain immune cells in Alzheimer Disease


2021 – 2023: Young Investigator Award, National Alliance for Research on Schizophrenia and Depression (Dong PI)


2019 – 2024: U01DA048279, National Institute on Drug Abuse (Roussos PI)
Functional genomic resource and integrative model of dopaminergic circuitry associated with psychiatric disease.


2019 – 2024: R01DA047880, National Institute on Drug Abuse (Roussos PI)
Transcriptome and epigenome mapping in dopamine neurons from the opioid exposed human brain.


2019 – 2021: Young Investigator Award, National Alliance for Research on Schizophrenia and Depression (Kim PI)
Integrative modelling approach for prioritizing rare risk variants in psychiatric diseases


2019 – 2021: Young Investigator Award, National Alliance for Research on Schizophrenia and Depression (Bendl PI)
Unraveling the mechanism underlying bipolar disorder by integrated analysis of gene expression, chromatin accessibility and genetic association studies


2018 – 2023: U01MH116442, National Institute of Mental Health (Roussos M-PI)
The 3D genome in transcriptional regulation across the postnatal life span, with implications for schizophrenia and bipolar disorder.


2018 – 2020: Merit BX004189, Veterans Administration (Roussos PI)
Large-scale transcriptome and epigenome association analysis across multiple traits.


2017 – 2020: RF1AG057440, National Institute of Aging (Roussos M-PI)
Towards a comprehensive signaling pathway map of parahippocampal vulnerability in Alzheimer’s Disease.


2017 – 2019: Boehringer Ingelheim, LTD (Roussos PI)
Multiregional assessment of cell type specific epigenome and transcriptional profiling in human brain tissue.


2016 – 2021: R01MH109677, National Institute of Mental Health (Roussos PI)
Risk genetic variants and cis regulation of gene expression in Bipolar Disorder.


2016 – 2021: R01MH109897, National Institute of Mental Health (Roussos M-PI)
Integrated Multiscale Networks in Schizophrenia.


2016 – 2020: R01MH110921, National Institute of Mental Health (Roussos PI)
Molecular Profiling of Schizophrenia.


2016 – 2021: Presidential Early Career Awards for Scientists and Engineers (PECASE), White House (Roussos PI)


2015 – 2020: R01AG050986, National Institute of Aging (Roussos PI)
Higher Order Chromatin and Genetic Risk for Alzheimer’s Disease.


2013 – 2022: Merit BX002395,Veterans Administration (Roussos PI)
Dissecting cis regulation of gene expression in schizophrenia.


 

 

Previous Funding

2016 – 2017: Research Grant, Charleston Conference on Alzheimer’s Disease
2015 – 2017: NIRG-340998, Alzheimer’s Association
2013 – 2015: Young Investigator Award, National Alliance for Research on Schizophrenia and Depression (NARSAD)
2013 – 2014: Research Grant, American Psychiatric Association (APA)

Contact Us

E-mail
Dr. Panos Roussos

Phone
Dr. Panos Roussos: (212) 824-8982
Dr. John Fullard: (212) 824-9125

Address
Roussos Lab
Icahn School of Medicine at Mount Sinai
1470 Madison Ave
The Leon and Norma Hess Center for Science and Medicine
Floor 9, Room 302, Box 1639
New York, NY 10029

Lab Location 
1470 Madison Avenue
Hess Center 9-302 (Lab), 9-107 (Office)
New York, NY 10029

Mail Address:
1470 Madison Avenue
Box 1639
New York, NY 10029